New combo aims to fix transfusion failure in blood cancer patients

NCT ID NCT07635511

Not yet recruiting Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether acalabrutinib (a BTK inhibitor) alone or with bortezomib can lower harmful HLA antibodies that cause platelet transfusions to fail in blood cancer patients. About 42 adults with platelet transfusion refractoriness and high antibody levels will be enrolled. The goal is to improve transfusion success and reduce bleeding.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: acalabrutinib maleate and bortezomib
What this could lead to: If successful, this could offer a way to make platelet transfusions work again for blood cancer patients, reducing bleeding risk and improving survival.
What could go wrong: This is a small early-phase trial (42 people) testing a new combination. It may not work for everyone, and side effects from the drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGICAL MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGICAL MALIGNANCIES HLA ANTIBODIES PLATELET TRANSFUSION REFRACTORINESS (PTR)

More trials for these conditions

Other studies related to the condition(s) this trial covers.